2026 Q2 -tulosraportti
9 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 130 | - | - | ||
| 100 | - | - | ||
| 250 | - | - | ||
| 309 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·33 min sittenI read on KI that Circio currently has over 20 different active research and development collaborations with different companies ongoing.... That sounds like an unusually large number. Isn't this quite unique ??
·24 min sitten · MuokattuIs there an agreement coming with Rocket Pharma in the heart disease Danon? Everyone who has followed Circio's presentations has heard the story of Rocket's Danon study with deaths due to excessively high medical dose and side effects. The medicine worked but a classic dosing problem. Circio started in autumn 2025 the work to create a therapeutic construct in Danon disease due to the strong heart data. We see from this year's presentations that Danon is no longer an internal focus project. It changed to much larger heart diseases and probably also relates to the collaboration with AvviGen and their good heart AAV capsides. What news did we nevertheless get now at the latest H1 presentation? Well, Circio had now for the first time received poc data from circVec studies in heart tissue. Which one? - well, LAMP2 which is the gene that fails in those who have Danon disease. For the first time, circVec-AAV heart expression advantage demonstrated with a therapeutic gene in vivo And Danon disease (DD) is a rare X‐linked dominant cardioskeletal myopathy caused by mutations in the lysosome‐associated membrane protein‐2 (LAMP2) gene. Circio has evidently internally not intended to focus on this project, but has nevertheless developed a circVec product with a therapeutic gene - which works. Who can then benefit from this circVec variant? Well, Rocket of course - if they use circVec they can significantly reduce the dose of their own effective gene medicine. Rocets has participated in conferences in Europe in the last half year. A bit special perhaps for such a USA-based company. Circio has several unknown collaborations - 4 in gene therapy. Is Rocket the one and are they first out? They need to get their project back on track. That could be a possibility for it as I see it.
- ·1 t sittenHold fast to what you own....this will be gold. Listen to what Wiklund says. Everything else is noise.
·2 t sittenMay I challenge your poor excuse for why you don't show your holdings
What would one use that for? Whether you have -99% or 200000% like for example bagnis. If you come with a solid argument about a company as well as links to various [sources]. Then I don't care what the return is. I myself have bought into a fundamentally solid company that just dives and dives because that's just how the market is. But the company is faultless in all its numbers. Whereas someone like spaceX is completely hyped up and their financial statements are crap. Investing in that is a gamble. It's hit or miss with spaceX. So I would never invest in that. And if one trades based on trends and TA, that's a gamble for me. And I don't want that. They must be fundamentally robust. But it also depends on many things. For example, is it a 59% return on 2500kr? Or 3 million. One doesn't know that either. Which influences what risky companies and trends people take. But also, how long has one been invested. Historically, one has returns in the long run in the stock market. There was an old asshole on the MPC site some time ago who has a Nordnet user that is incredibly old, who also had a decent return. And every time one presented an argument against him or was questioning, he always brought up "what is your return, if they profile, I have better returns than you, so I am right". So that's also something people use for a form of credibility. Especially for people who can't do their own analysis, they look at what others do. But if a man with 127% return says the earth is flat, would one believe him? No, right. But no matter what return one has. If one has a solid argument, analysis, and evidence. Then I can't see why one shouldn't stop and listen (and of course remain critical).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
9 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·33 min sittenI read on KI that Circio currently has over 20 different active research and development collaborations with different companies ongoing.... That sounds like an unusually large number. Isn't this quite unique ??
- ·24 min sitten · MuokattuIs there an agreement coming with Rocket Pharma in the heart disease Danon? Everyone who has followed Circio's presentations has heard the story of Rocket's Danon study with deaths due to excessively high medical dose and side effects. The medicine worked but a classic dosing problem. Circio started in autumn 2025 the work to create a therapeutic construct in Danon disease due to the strong heart data. We see from this year's presentations that Danon is no longer an internal focus project. It changed to much larger heart diseases and probably also relates to the collaboration with AvviGen and their good heart AAV capsides. What news did we nevertheless get now at the latest H1 presentation? Well, Circio had now for the first time received poc data from circVec studies in heart tissue. Which one? - well, LAMP2 which is the gene that fails in those who have Danon disease. For the first time, circVec-AAV heart expression advantage demonstrated with a therapeutic gene in vivo And Danon disease (DD) is a rare X‐linked dominant cardioskeletal myopathy caused by mutations in the lysosome‐associated membrane protein‐2 (LAMP2) gene. Circio has evidently internally not intended to focus on this project, but has nevertheless developed a circVec product with a therapeutic gene - which works. Who can then benefit from this circVec variant? Well, Rocket of course - if they use circVec they can significantly reduce the dose of their own effective gene medicine. Rocets has participated in conferences in Europe in the last half year. A bit special perhaps for such a USA-based company. Circio has several unknown collaborations - 4 in gene therapy. Is Rocket the one and are they first out? They need to get their project back on track. That could be a possibility for it as I see it.
- ·1 t sittenHold fast to what you own....this will be gold. Listen to what Wiklund says. Everything else is noise.
- ·2 t sittenMay I challenge your poor excuse for why you don't show your holdingsWhat would one use that for? Whether you have -99% or 200000% like for example bagnis. If you come with a solid argument about a company as well as links to various [sources]. Then I don't care what the return is. I myself have bought into a fundamentally solid company that just dives and dives because that's just how the market is. But the company is faultless in all its numbers. Whereas someone like spaceX is completely hyped up and their financial statements are crap. Investing in that is a gamble. It's hit or miss with spaceX. So I would never invest in that. And if one trades based on trends and TA, that's a gamble for me. And I don't want that. They must be fundamentally robust. But it also depends on many things. For example, is it a 59% return on 2500kr? Or 3 million. One doesn't know that either. Which influences what risky companies and trends people take. But also, how long has one been invested. Historically, one has returns in the long run in the stock market. There was an old asshole on the MPC site some time ago who has a Nordnet user that is incredibly old, who also had a decent return. And every time one presented an argument against him or was questioning, he always brought up "what is your return, if they profile, I have better returns than you, so I am right". So that's also something people use for a form of credibility. Especially for people who can't do their own analysis, they look at what others do. But if a man with 127% return says the earth is flat, would one believe him? No, right. But no matter what return one has. If one has a solid argument, analysis, and evidence. Then I can't see why one shouldn't stop and listen (and of course remain critical).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 130 | - | - | ||
| 100 | - | - | ||
| 250 | - | - | ||
| 309 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
9 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·33 min sittenI read on KI that Circio currently has over 20 different active research and development collaborations with different companies ongoing.... That sounds like an unusually large number. Isn't this quite unique ??
- ·24 min sitten · MuokattuIs there an agreement coming with Rocket Pharma in the heart disease Danon? Everyone who has followed Circio's presentations has heard the story of Rocket's Danon study with deaths due to excessively high medical dose and side effects. The medicine worked but a classic dosing problem. Circio started in autumn 2025 the work to create a therapeutic construct in Danon disease due to the strong heart data. We see from this year's presentations that Danon is no longer an internal focus project. It changed to much larger heart diseases and probably also relates to the collaboration with AvviGen and their good heart AAV capsides. What news did we nevertheless get now at the latest H1 presentation? Well, Circio had now for the first time received poc data from circVec studies in heart tissue. Which one? - well, LAMP2 which is the gene that fails in those who have Danon disease. For the first time, circVec-AAV heart expression advantage demonstrated with a therapeutic gene in vivo And Danon disease (DD) is a rare X‐linked dominant cardioskeletal myopathy caused by mutations in the lysosome‐associated membrane protein‐2 (LAMP2) gene. Circio has evidently internally not intended to focus on this project, but has nevertheless developed a circVec product with a therapeutic gene - which works. Who can then benefit from this circVec variant? Well, Rocket of course - if they use circVec they can significantly reduce the dose of their own effective gene medicine. Rocets has participated in conferences in Europe in the last half year. A bit special perhaps for such a USA-based company. Circio has several unknown collaborations - 4 in gene therapy. Is Rocket the one and are they first out? They need to get their project back on track. That could be a possibility for it as I see it.
- ·1 t sittenHold fast to what you own....this will be gold. Listen to what Wiklund says. Everything else is noise.
- ·2 t sittenMay I challenge your poor excuse for why you don't show your holdingsWhat would one use that for? Whether you have -99% or 200000% like for example bagnis. If you come with a solid argument about a company as well as links to various [sources]. Then I don't care what the return is. I myself have bought into a fundamentally solid company that just dives and dives because that's just how the market is. But the company is faultless in all its numbers. Whereas someone like spaceX is completely hyped up and their financial statements are crap. Investing in that is a gamble. It's hit or miss with spaceX. So I would never invest in that. And if one trades based on trends and TA, that's a gamble for me. And I don't want that. They must be fundamentally robust. But it also depends on many things. For example, is it a 59% return on 2500kr? Or 3 million. One doesn't know that either. Which influences what risky companies and trends people take. But also, how long has one been invested. Historically, one has returns in the long run in the stock market. There was an old asshole on the MPC site some time ago who has a Nordnet user that is incredibly old, who also had a decent return. And every time one presented an argument against him or was questioning, he always brought up "what is your return, if they profile, I have better returns than you, so I am right". So that's also something people use for a form of credibility. Especially for people who can't do their own analysis, they look at what others do. But if a man with 127% return says the earth is flat, would one believe him? No, right. But no matter what return one has. If one has a solid argument, analysis, and evidence. Then I can't see why one shouldn't stop and listen (and of course remain critical).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 130 | - | - | ||
| 100 | - | - | ||
| 250 | - | - | ||
| 309 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt